Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Working to Help Employers Tackle Cardiovascular Risk, Healthcare Costs
- Cardiovascular disease remains one of the most expensive health conditions in the United States.
- Cardio Diagnostics announced plans to participate in four national benefits conferences during June.
- The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care.
A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for employee benefits are seeking new strategies to identify risk earlier and improve outcomes. Cardio Diagnostics Holdings (NASDAQ: CDIO) is engaging directly with these stakeholders at four national benefits conferences in June, where the company plans to discuss innovative approaches to cardiovascular disease prevention, risk assessment and cost management.
According to the American Heart Association (“AHA”), cardiovascular disease remains one of the most expensive health conditions in the United States. Direct cardiovascular healthcare costs accounted for approximately 11% of all U.S. healthcare expenditures in 2020–2021, more than any major diagnostic category except musculoskeletal disorders. The AHA also projects that annual cardiovascular healthcare costs will rise from approximately $393 billion in 2020 to nearly $1.5 trillion by 2050, while productivity losses are expected to increase from $234 billion to $361 billion over the same period.
For employers and health insurers, these costs often translate into increased claims expenses, higher premiums and greater utilization of healthcare resources. The Centers for Disease Control and Prevention reports that heart disease remains the leading cause of death in the United States and continues to generate substantial direct medical expenditures as well as indirect costs related to lost productivity. Cardiovascular conditions frequently require ongoing treatment, specialist care, medications and, in many cases, hospitalization, creating a significant burden for self-funded employer plans and insurance providers alike.
Enter Cardio Diagnostics. The company recently announced plans to participate in four national benefits conferences during June, where the company will engage employers, brokers, union trustees and plan administrators on strategies for addressing cardiovascular disease. According to the company, the presentations are intended to highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management.
The company’s message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from tools that help identify elevated risk or silent disease before they progress. This preventive focus aligns with broader trends in healthcare, where organizations are increasingly emphasizing population health management and proactive risk reduction.
Cardio Diagnostics has developed a suite of solutions intended to support these goals. Epi+Gen CHD(TM) is designed to assess an individual’s likelihood of having a coronary heart disease event, including a heart attack, by integrating epigenetic and genetic biomarkers with artificial intelligence–driven analysis. By examining molecular signals captured through a blood sample, the test seeks to provide personalized cardiovascular insights that complement traditional risk assessments.
The company’s PrecisionCHD(TM) solution is designed to assist in the diagnosis and management of coronary heart disease. One of the most significant aspects of the PrecisionCHD test is data that indicates its ability to detect nonobstructive forms of coronary heart disease, specifically ischemia with no obstructive coronary arteries (“INOCA”) and myocardial infarction with no obstructive coronary arteries (“MINOCA”). Standard tests, including angiograms, can miss this detection.
Both tests are noninvasive, and neither one requires fasting or radiation. In addition, they can be performed at home using a sample collection kit ordered through a telemedicine platform.
For employers and health plans, the company also offers the HeartRisk(TM) population insights platform. HeartRisk is designed to help organizations identify cardiovascular risk across larger populations, enabling more precise population health initiatives. Such capabilities may be particularly relevant for self-funded employers and benefit administrators seeking to improve employee health outcomes while managing long-term healthcare expenditures.
Artificial intelligence plays a central role across these offerings. Cardio Diagnostics combines genetic and epigenetic biomarkers with AI-driven analytics to identify patterns associated with cardiovascular disease risk. The company describes this approach as part of its broader effort to advance precision cardiovascular medicine through more personalized and data-driven insights.
The company’s participation in national benefits conferences reflects growing recognition that cardiovascular disease is not only a clinical challenge but also a major economic concern for employers and insurers. As healthcare costs continue to rise, benefit decision-makers are increasingly evaluating solutions that emphasize prevention, early detection and personalized care. By presenting its technologies and population health strategies to employers, brokers and plan administrators, Cardio Diagnostics is positioning itself within an evolving conversation about how healthcare organizations can address one of the most costly and impactful disease categories affecting both patients and payors.
For more information, visit www.CDIO.ai.
NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Cardiovascular disease remains one of the most expensive health conditions in the United States.
- Cardio Diagnostics announced plans to participate in four national benefits conferences during June.
- The company has developed a suite of solutions designed to provide earlier identification of cardiovascular risk and enable more targeted interventions and preventive care.
A single heart attack or major cardiovascular event can have consequences that extend far beyond a patient’s health, affecting employers, insurers and healthcare systems through higher medical costs, lost productivity and long-term care expenses. As cardiovascular disease continues to drive a significant share of healthcare spending, organizations responsible for employee benefits are seeking new strategies to identify risk earlier and improve outcomes. Cardio Diagnostics Holdings (NASDAQ: CDIO) is engaging directly with these stakeholders at four national benefits conferences in June, where the company plans to discuss innovative approaches to cardiovascular disease prevention, risk assessment and cost management.
According to the American Heart Association (“AHA”), cardiovascular disease remains one of the most expensive health conditions in the United States. Direct cardiovascular healthcare costs accounted for approximately 11% of all U.S. healthcare expenditures in 2020–2021, more than any major diagnostic category except musculoskeletal disorders. The AHA also projects that annual cardiovascular healthcare costs will rise from approximately $393 billion in 2020 to nearly $1.5 trillion by 2050, while productivity losses are expected to increase from $234 billion to $361 billion over the same period.
For employers and health insurers, these costs often translate into increased claims expenses, higher premiums and greater utilization of healthcare resources. The Centers for Disease Control and Prevention reports that heart disease remains the leading cause of death in the United States and continues to generate substantial direct medical expenditures as well as indirect costs related to lost productivity. Cardiovascular conditions frequently require ongoing treatment, specialist care, medications and, in many cases, hospitalization, creating a significant burden for self-funded employer plans and insurance providers alike.
Enter Cardio Diagnostics. The company recently announced plans to participate in four national benefits conferences during June, where the company will engage employers, brokers, union trustees and plan administrators on strategies for addressing cardiovascular disease. According to the company, the presentations are intended to highlight how advanced cardiovascular risk assessment and detection tools can support both improved health outcomes and more effective healthcare cost management.
The company’s message centers on the idea that earlier identification of cardiovascular risk and disease can potentially enable more targeted interventions and preventive care. Rather than waiting until symptoms develop or major events occur, employers and health plans may benefit from tools that help identify elevated risk or silent disease before they progress. This preventive focus aligns with broader trends in healthcare, where organizations are increasingly emphasizing population health management and proactive risk reduction.
Cardio Diagnostics has developed a suite of solutions intended to support these goals. Epi+Gen CHD(TM) is designed to assess an individual’s likelihood of having a coronary heart disease event, including a heart attack, by integrating epigenetic and genetic biomarkers with artificial intelligence–driven analysis. By examining molecular signals captured through a blood sample, the test seeks to provide personalized cardiovascular insights that complement traditional risk assessments.
The company’s PrecisionCHD(TM) solution is designed to assist in the diagnosis and management of coronary heart disease. One of the most significant aspects of the PrecisionCHD test is data that indicates its ability to detect nonobstructive forms of coronary heart disease, specifically ischemia with no obstructive coronary arteries (“INOCA”) and myocardial infarction with no obstructive coronary arteries (“MINOCA”). Standard tests, including angiograms, can miss this detection.
Both tests are noninvasive, and neither one requires fasting or radiation. In addition, they can be performed at home using a sample collection kit ordered through a telemedicine platform.
For employers and health plans, the company also offers the HeartRisk(TM) population insights platform. HeartRisk is designed to help organizations identify cardiovascular risk across larger populations, enabling more precise population health initiatives. Such capabilities may be particularly relevant for self-funded employers and benefit administrators seeking to improve employee health outcomes while managing long-term healthcare expenditures.
Artificial intelligence plays a central role across these offerings. Cardio Diagnostics combines genetic and epigenetic biomarkers with AI-driven analytics to identify patterns associated with cardiovascular disease risk. The company describes this approach as part of its broader effort to advance precision cardiovascular medicine through more personalized and data-driven insights.
The company’s participation in national benefits conferences reflects growing recognition that cardiovascular disease is not only a clinical challenge but also a major economic concern for employers and insurers. As healthcare costs continue to rise, benefit decision-makers are increasingly evaluating solutions that emphasize prevention, early detection and personalized care. By presenting its technologies and population health strategies to employers, brokers and plan administrators, Cardio Diagnostics is positioning itself within an evolving conversation about how healthcare organizations can address one of the most costly and impactful disease categories affecting both patients and payors.
For more information, visit www.CDIO.ai.
NOTE TO INVESTORS: The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
